Background Thyroid cancer is the second most common malignancy among females at King
Faisal Specialist Hospital and Research Centre (KFSH&RC) and in Saudi Arabia …

Thyroid cancer is the most frequent type of cancers originating from the endocrine system.
Early diagnosis leads to good clinical outcome in differentiated types of thyroid cancer. Yet …

Background Lenvatinib has been approved by regulatory agencies in Japan, the United
States, and the European Union for treatment of radioiodine-refractory differentiated thyroid …

Background We report results from the phase I dose-finding and phase II expansion part of a
multicenter, open-label study of single-agent lenvatinib in pediatric and young adult patients …

Abstract Background In the phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of
the Thyroid (SELECT), lenvatinib significantly improved efficacy outcomes versus placebo in …

Background: Thyroid cancer is the most common endocrine tumor. Our previous studies
have demonstrated that curcumin can induce apoptosis in human papillary thyroid …

Thyroid cancers are the most frequent neoplasms of the endocrine system and in the initial
stages their prognosis is excellent. However, few therapeutic options are available for …

Background. Lenvatinib has proven efficacy in progressive, radioiodine‐(RAI‐) refractory
thyroid cancer (TC). Dose reductions are commonly performed due to decreased tolerability …

Objective Anlotinib, a novel multitarget kinase inhibitor of VEGFR, FGFR, PDGFR and c-Kit,
has proven to be effective and safe for refractory soft tissue sarcoma patients, but has not …

Fibroblast growth factor 21 (FGF21) plays important roles in regulating glucose, lipid, and
energy metabolism; however, its effects in tumors remain poorly understood. To understand …